Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMLi-2
Description: Potent and selective LRRK2 inhibitor
Chemical Name: rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidyl]-5-[(1-methylcyclopropyl)oxy]-1H-indazole
Purity: ≥98% (HPLC)
Biological Activity for MLi-2
MLi-2 is a potent and selective LRRK2 inhibitor (IC50 = 0.76-3.4 nM depending on assay), which exhibits >295-fold selectivity for over 300 kinases and a diverse panel of receptors and ion channels. MLi-2 is centrally bioavailable and active in vivo.
External Portal Information for MLi-2
Chemicalprobes.org and the Chemical Probes webpages of the Structural Genomics Consortium are portals that offer independent guidance on the selection and/or application of small molecules for research. The use of MLi-2 is reviewed on chemicalprobes.org and the SGC website.
Compound Libraries for MLi-2
MLi-2 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.
Technical Data for MLi-2
| M. Wt | 379.46 |
| Formula | C21H25N5O2 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1627091-47-7 |
| PubChem ID | 78319901 |
| InChI Key | ATUUNJCZCOMUKD-OKILXGFUSA-N |
| Smiles | CC1(CC1)OC2=CC=C3C(C(C4=NC=NC(N5C[C@@H](C)O[C@@H](C)C5)=C4)=NN3)=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for MLi-2
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 18.97 | 50 |
Preparing Stock Solutions for MLi-2
The following data is based on the product molecular weight 379.46. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 5.27 mL | 26.35 mL | 52.71 mL |
| 2.5 mM | 1.05 mL | 5.27 mL | 10.54 mL |
| 5 mM | 0.53 mL | 2.64 mL | 5.27 mL |
| 25 mM | 0.11 mL | 0.53 mL | 1.05 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for MLi-2
References for MLi-2
References are publications that support the biological activity of the product.
Fell et al (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J.Pharmacol.Exp.Ther. 355 397 PMID: 26407721
If you know of a relevant reference for MLi-2, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MLi-2, MLi-2 supplier, leucine-rich, repeat, kinase, 2, LRRK2, inhibitors, inhibits, potent, neuroprotective, neuronal, injury, parkinson's, parkinsons, 5756, Tocris Bioscience
22 Citations for MLi-2
Citations are publications that use Tocris products. Selected citations for MLi-2 include:
Yuriko et al (2021) Pathogenic LRRK2 regulates ciliation probability upstream of tau tubulin kinase 2 via Rab10 and RILPL1 proteins. Proc Natl Acad Sci U S A 118 PMID: 33653948
John Q et al (2021) LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons. J Parkinsons Dis 11 1187-1196 PMID: 33720852
Dan et al (2021) Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. Curr Biol 31 2140-2154.e6 PMID: 33765413
Chelsie A et al (2021) Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition. Mol Brain 14 143 PMID: 34530877
Vincent et al (2022) A cell-based GEF assay reveals new substrates for DENN domains and a role for DENND2B in primary ciliogenesis. Sci Adv 8 eabk3088 PMID: 35196081
Sven H et al (2022) Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2. Proc Natl Acad Sci U S A 119 PMID: 35217606
Sung-Woo et al (2022) LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. Cells 11 PMID: 35269482
Elisa et al (2022) Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease. Acta Neuropathol 144 81-106 PMID: 35596783
Mark R et al (2022) Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment. Neurobiol Dis 170 105769 PMID: 35580815
Nicolas et al (2022) WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes. Front Cell Neurosci 16 892899 PMID: 35755775
Catherine et al (2022) DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy. Brain 145 4368-4384 PMID: 36039535
Mark R et al (2022) Lysosomal positioning regulates Rab10 phosphorylation at LRRK2+ lysosomes. Proc Natl Acad Sci U S A 119 e2205492119 PMID: 36256825
Ole et al (2019) Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. Hum Mol Genet 28 3232-3243 PMID: 31261377
Matthias et al (2020) Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease. Mol Cell Proteomics 19 1546-1560 PMID: 33451735
Weidong et al (2020) Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging. Mol Neurodegener 15 12 PMID: 32075681
Shaun et al (2020) LRRK2 mutations impair depolarization-induced mitophagy through inhibition of mitochondrial accumulation of RAB10. Autophagy 16 203-222 PMID: 30945962
Ravindran et al (2020) LRRK2 mediates tubulation and vesicle sorting from lysosomes. Sci Adv 6 PMID: 33177079
Huw R et al (2020) LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO J 39 e104494 PMID: 32643832
Matthias et al (2020) Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease. Mol Cell Proteomics 19 1546-1560 PMID: 32601174
Eleanor T et al (2020) Protein synthesis is suppressed in sporadic and familial Parkinson's disease by LRRK2. FASEB J 34 14217-14233 PMID: 32926469
Henderikus et al (2023) Characterization of Lipopolysaccharide Effects on LRRK2 Signaling in RAW Macrophages. Int J Mol Sci 24 PMID: 36675159
Henderson et al (2018) LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Acta Neuropathol Commun 6 45 PMID: 29855356
Do you know of a great paper that uses MLi-2 from Tocris? Please let us know.
Reviews for MLi-2
Average Rating: 4 (Based on 1 Review.)
Have you used MLi-2?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Good LRRK2 inhibitor.
By
Anonymous on 01/27/2023
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: Primary hippocampal neurons
The drug was incubated at 500 nM to inhibit LRRK2.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.